Coherus Oncology, Inc.

CHRS

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001512762

SEC filings (opens in a new tab)

No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Coherus Oncology, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021 All holders in Q2 2021

13F holders of CHRS: Q2 2021 compared with Q3 2021
Measure	Q2 2021	Of which not filed for Q3 2021	Q3 2021	Change
Holders	188	1	188	+1
Shares	77.9M	158.6K	76.1M	−1.58M (−2.0%)
Value	$1.08B	$2.19M	$1.22B	+$149.0M (+13.9%)

1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Coherus Oncology, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to CHRS in Q3 2021
Institution	Shares	Value	% of portfolio
Suvretta Capital Management, LLC	489,333	$7.86M	0.13%
Fred Alger Management, LLC	432,434	$6.95M	0.02%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	190,401	$3.06M	0.00%
Pictet Asset Management SA	158,575	$2.55M	0.00%
HRT Financial LP	98,000	$1.57M	0.01%
SG Americas Securities, LLC	86,200	$1.39M	0.01%
FinTrust Capital Advisors, LLC	27,500	$442.0K	0.12%
ExodusPoint Capital Management, LP	27,079	$435.0K	0.01%
Maryland State Retirement & Pension System	24,977	$409.0K	0.01%
Zebra Capital Management LLC	22,918	$368.0K	0.45%
Metropolitan Life Insurance Co	17,813	$286.3K	0.00%
Natixis Advisors, L.P.	14,840	$238.0K	0.00%
Ergoteles LLC	13,600	$219.0K	0.01%
Tibra Equities Europe Ltd	13,500	$217.0K	0.33%
CWM Advisors, LLC	13,200	$212.0K	0.03%
Federated Hermes, Inc.	11,131	$179.0K	0.00%
FDx Advisors, Inc.	10,477	$168.0K	0.01%
Ellevest, Inc.	489	$8.00K	0.00%
Fifth Third Bancorp	112	$2.00K	0.00%
Meeder Asset Management Inc	75	$1.00K	0.00%
Signaturefd, LLC	45	$1.00K	0.00%
Meridian Wealth Partners, LLC	9	$0	0.00%

Sold out (21)

Institutions that held Coherus Oncology, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of CHRS in Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Sofinnova Investments, Inc.	434,555	$6.01M
Sio Capital Management, LLC	413,733	$5.72M
Wellington Management Group LLP	349,305	$4.83M
Rice Hall James & Associates, LLC	213,748	$2.96M
Squarepoint Ops LLC	116,257	$1.61M
Jefferies Group LLC	110,285	$1.53M
Mirae Asset Global Investments Co., Ltd.	102,449	$1.42M
Assenagon Asset Management S.A.	91,886	$1.27M
AlphaCrest Capital Management LLC	76,800	$1.06M
First Trust Advisors LP	39,093	$541.0K
Exchange Traded Concepts, LLC	32,659	$452.0K
Glenmede Trust Co NA	30,559	$422.0K
Janus Henderson Group PLC	19,224	$266.0K
Point72 Hong Kong Ltd	17,617	$244.0K
Gsa Capital Partners LLP	12,453	$172.0K
Caption Management, LLC	12,000	$167.0K
Amundi	10,994	$152.0K
6 Meridian	10,882	$150.0K
HSBC Holdings PLC	10,556	$147.0K
Panagora Asset Management Inc	110	$2.00K
Toronto Dominion Bank	53	$1.00K

Not filed for Q3 2021 yet (1)

Institutions that held Coherus Oncology, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CHRS in Q2 2021 that haven't filed for Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Pictet Asset Management Ltd	158,575	$2.19M